Synaptogenix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNPX research report →
About the company
Synaptogenix, Inc. operates as a biopharmaceutical entity, actively advancing multiple product candidates through both preclinical and clinical development stages. The company's primary focus involves establishing a therapeutic platform centered on Bryostatin-1, a key drug candidate, primarily for the treatment of Alzheimer's disease.
- CEO
- Alan J. Tuchman MBA(FAAN)
- IPO
- 2020
- Employees
- 4
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $10.91M
- P/E
- -0.27
- P/S
- 17.49
- P/B
- 1.05
- EV/EBITDA
- -0.90
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1453.20%
- Net Margin
- -3615.43%
- ROE
- -120.29%
- ROIC
- -33.38%
- Revenue
- $0 · 0.00%
- Net Income
- $-29,075,807,000 · -227614.26%
- EPS
- $-8.81 · 19.84%
- Op Income
- $-9,047,157,000
- FCF YoY
- -130838.28%
- 52W High
- $8.94
- 52W Low
- $1.84
- 50D MA
- $3.64
- 200D MA
- $3.08
- Beta
- 1.30
- Avg Volume
- 933.14K
Get TickerSpark's AI analysis on SNPX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 3, 25 | Singer William S. | other | 800 |
| Apr 3, 25 | SCHECHTER JONATHAN | other | 800 |
| Apr 3, 25 | Bernstein Bruce | other | 800 |
| Apr 8, 24 | Singer William S. | other | 800 |
| Apr 8, 24 | Silverman Joshua | other | 800 |
| Apr 8, 24 | SCHECHTER JONATHAN | other | 800 |
| Apr 8, 24 | Bernstein Bruce | other | 800 |
| Mar 29, 23 | SCHECHTER JONATHAN | other | 20,000 |
| Mar 29, 23 | Singer William S. | other | 20,000 |
| Mar 29, 23 | Bernstein Bruce | other | 20,000 |
Our SNPX coverage
Recent articles, reports, and earnings notes.
No research on SNPX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNPX report →Similar companies
Peers in the same neighborhood.